Form 4: Nurix Therapeutics CFO Hans van Houte Reports Stock Transactions

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposition of common stock and restricted stock units to cover tax obligations.

Summary

• On July 30, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
• Van Houte acquired shares through the vesting of RSUs and disposed of shares to cover tax withholding obligations.
• Specifically, 2,886, 2,000 and 3,750 shares were acquired through RSU vesting.
• A total of 2,490 shares were sold at a weighted average price of $20.6677 to satisfy tax obligations related to the vesting of RSUs.
• Following these transactions, van Houte beneficially owns 54,479 shares of common stock and varying amounts of RSUs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It is typical for executives to receive stock options or RSUs as part of their compensation and to sell shares to cover tax obligations upon vesting.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a company insider, but the impact is likely minimal given the context of tax obligations.

Key Dates